Sanofi and Regeneron’s Dupixent shows promising results in Phase 3 eczema trial

Sanofi and Regeneron Pharmaceuticals have achieved a significant milestone with their jointly developed eczema drug, Dupixent (dupilumab), meeting the primary endpoints in a year-long Phase ... Read More